心力衰竭试验中性别差异原因评估
女性患者中位占比为25.8%,在缺血性心肌病、严重收缩功能障碍及侵入性操作试验中最低,而在射血分数保留的心衰和老年参与者试验中最高。女性试验参与率与人群患病率在所有LVEF类别中均存在显著差异(25.8% vs 49.0%,p<0.01)。
要点
- 心衰试验中女性中位占比仅25.8%,显著低于人群患病率49.0%。
- 缺血性心肌病、LVEF<35%及侵入性操作试验中女性比例最低。
- 射血分数保留的心衰和老年参与者试验中女性比例最高。
核心结论
- 心衰试验存在显著性别差异,尤其在严重射血分数降低和缺血性病因试验中最为明显。
- 这种差异可能源于入组偏倚与生物学变异的复杂交互,且程度因试验类型而异。
研究设计与样本
- 研究识别了2000至2020年间发表于七本影响因子>20的临床期刊的心衰试验,纳入参与者超过300例且男女均有。
主要发现
- 女性患者中位占比为25.8%。
- 缺血性心肌病试验女性占比17.9%,LVEF<35%试验为21.4%,侵入性操作试验为21.1%。
- 射血分数保留的心衰试验女性占比51.6%,老年参与者试验为40.5%。
- 女性试验参与率与人群患病率在所有LVEF类别中均存在显著差异(25.8% vs 49.0%,p<0.01)。
临床怎么用
- 未来应鼓励所有心衰试验评估其招募日志,并建议解释任何报告的性别差异原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cardiovascular disease is one of the leading causes of mortality and morbidity in women. Despite this, even in contemporary research, female patients are poorly represented in trials. This study aimed to explore reasons behind the sex disparity in heart failure (HF) trials. METHODS: HF trials published in seven high-impact clinical journals (impact factor >20), between 2000 and 2020, were identified. Trials with over 300 participants of both sexes were included. Large HF registries, as well as population statistics, were also identified using the same criteria. RESULTS: We identified 146 HF trials, which included 248 620 patients in total. The median proportion of female patients was 25.8%, with the lowest proportions seen in trials enrolling patients with ischaemic cardiomyopathy (17.9%), severe systolic dysfunction (left ventricular ejection fraction (LVEF) <35%) (21.4%) and those involving an invasive procedure (21.1%). The highest proportion of women was seen in trials assessing HF with preserved LVEF (51.6%), as well as trials including older participants (40.5%). Significant differences were seen between prevalence of female trial participants and population prevalence in all LVEF categories (25.8% vs 49.0%, p<0.01). CONCLUSIONS: A significant sex disparity was identified in HF trials, most visible in trials assessing patients with severely reduced LVEF and ischaemic aetiology. This is likely due to a complex interplay between enrolment bias and biological variation. Furthermore, the degree of both these aspects may vary according to trial type. Going forward, we should encourage all HF trials to appraise their recruitment log and suggest reasons for any reported sex disparity.
引用
- Morgan H, Sinha A, Mcentegart M, et al. Evaluation of the causes of sex disparity in heart failure trials. Heart. 2022. PMID: 35361671. doi:10.1136/heartjnl-2021-320696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。